Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 · New England Journal of Medicine · 2,779 citations
https://doi.org/10.1056/nejmoa1215734
S
Silvio Danese
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2.3K
Papers
87.1K
Citations
139
h-index
906
i10-index
Silvio Danese is an academic researcher from Western University. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 139, co-authored 1973 publications.
ORCID: 0000-0001-7341-1351Papers by this author
worksSTRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 · Gastroenterology · 2,504 citations
https://doi.org/10.1053/j.gastro.2020.12.031
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
2015 · The American Journal of Gastroenterology · 1,784 citations
https://doi.org/10.1038/ajg.2015.233
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
2017 · New England Journal of Medicine · 1,664 citations
https://doi.org/10.1056/nejmoa1606910
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019 · New England Journal of Medicine · 1,130 citations
https://doi.org/10.1056/nejmoa1900750
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
2017 · The Lancet · 883 citations
https://doi.org/10.1016/s0140-6736(17)32641-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat